{"id":881,"date":"2016-01-28T13:42:59","date_gmt":"2016-01-28T13:42:59","guid":{"rendered":"http:\/\/cbb.uw.edu.pl\/en\/?page_id=881"},"modified":"2024-03-19T14:58:02","modified_gmt":"2024-03-19T14:58:02","slug":"pharmabusiness-ethics-and-biopolitics","status":"publish","type":"page","link":"https:\/\/cbb.uw.edu.pl\/en\/grants\/pharmabusiness-ethics-and-biopolitics\/","title":{"rendered":"Pharmabusiness, ethics and biopolitics"},"content":{"rendered":"<p><a href=\"https:\/\/cbb.uw.edu.pl\/wp-content\/uploads\/2024\/03\/logo-NCN-horozin-en.png\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-10642 alignnone\" src=\"https:\/\/cbb.uw.edu.pl\/wp-content\/uploads\/2024\/03\/logo-NCN-horozin-en.png\" alt=\"\" width=\"401\" height=\"35\" srcset=\"https:\/\/cbb.uw.edu.pl\/wp-content\/uploads\/2024\/03\/logo-NCN-horozin-en.png 3082w, https:\/\/cbb.uw.edu.pl\/wp-content\/uploads\/2024\/03\/logo-NCN-horozin-en-300x26.png 300w, https:\/\/cbb.uw.edu.pl\/wp-content\/uploads\/2024\/03\/logo-NCN-horozin-en-1024x89.png 1024w, https:\/\/cbb.uw.edu.pl\/wp-content\/uploads\/2024\/03\/logo-NCN-horozin-en-768x67.png 768w, https:\/\/cbb.uw.edu.pl\/wp-content\/uploads\/2024\/03\/logo-NCN-horozin-en-1536x134.png 1536w, https:\/\/cbb.uw.edu.pl\/wp-content\/uploads\/2024\/03\/logo-NCN-horozin-en-2048x178.png 2048w, https:\/\/cbb.uw.edu.pl\/wp-content\/uploads\/2024\/03\/logo-NCN-horozin-en-660x57.png 660w\" sizes=\"auto, (max-width: 401px) 100vw, 401px\" \/><\/a><\/p>\n<p><strong><span style=\"color: #ff0000;\">PROJECT SETTLED\u00a0<\/span><\/strong><\/p>\n<p>Project title:\u00a0<span style=\"color: #16a1e7;\"><strong>Activity of pharmaceutical industry &#8211; ethical challenges and new biopolitics<\/strong><\/span><br \/>\nPrincipal investigator: <strong>d<\/strong><strong>r Emilia Kaczmarek<\/strong><br \/>\nFinancing: National Science Centre,\u00a0Preludium\u00a09<br \/>\nProject Period: 2016-2018<br \/>\nProject no.\u00a02015\/17\/N\/HS1\/02122<\/p>\n<p><strong>Project goals:\u00a0<\/strong>The main objective of the project is to demonstrate the biopolitical nature of the activity of pharmaceutical industry and to evaluate this activity from the point of view of bioethics. Research on particular strategies of the pharmaceutical industry will be divided into three parts. In the first part, the different forms of pharmaceutical lobbying will be characterized. In the second part, the matter of analysis will be the pharma marketing and the third part will be devoted to the commercialization of knowledge in the drug industry. The objective of the proposed project is to gain knowledge about the nature of the various strategies of the pharmaceutical industry, through deep analysis of such concepts as medicalization of life (in the context of pharmaceutical marketing and, in particular, in the context of so called disease branding\/disease mongering) or commercialization of knowledge (inter alia in the context of control over the results of clinical trials sponsored by the pharmaceutical industry). Particular stages of the project will be devoted to different research questions, such as, for example: which of the existing concept of biopolitics gives the best tools for understanding the drug industry, what role plays lobbying in the democracy or what social consequences entail selected strategies of advertising drugs?<\/p>\n<p><strong><span style=\"color: #00ffff;\"><a style=\"color: #16a1e7;\" href=\"https:\/\/ncn.gov.pl\/sites\/default\/files\/listy-rankingowe\/2015-03-15\/streszczenia\/292225-en.pdf\">Popular summary<\/a><\/span><\/strong><\/p>\n<p><strong>Keywords:<\/strong>\u00a0biopolitics, pharmabusiness, medicalisation,\u00a0commercialisation of knowledge<\/p>\n<hr \/>\n<p>Publication of the project results<\/p>\n<p><strong>Papers:<\/strong><\/p>\n<ul>\n<li><strong>Kaczmarek<\/strong>, E. (2018).\u00a0<a href=\"https:\/\/link.springer.com\/article\/10.1007%2Fs11019-018-9850-1#\">How to distinguish medicalization from over-medicalization?.\u00a0<\/a><em>Medicine, Health Care and Philosophy, <\/em>doi:\u00a010.1007\/s11019-018-9850-1<\/li>\n<li><strong>Kaczmarek,\u00a0<\/strong>E. (2017).\u00a0<a href=\"http:\/\/www.prawoimedycyna.pl\/index.php?str=artykul&amp;id=1540\">Relacje firm farmaceutycznych i organizacji pacjent\u00f3w w Polsce \u2013 szansa czy zagro\u017cenie?<\/a>,\u00a0<em>Prawo i Medycyna<\/em>\u00a03 (68, vol. 19), 23-41.<\/li>\n<li><strong>Kaczmarek<\/strong>, E. (2016). <a href=\"https:\/\/www.ceeol.com\/search\/article-detail?id=578469\">Nowe wcielenie biopolityki<\/a>. <em>Civitas. Studia z filozofii polityki<\/em>, 19, 281-293.<\/li>\n<\/ul>\n<p><strong>Conference presentations:<\/strong><\/p>\n<ul>\n<li><strong>Kaczmarek,<\/strong>\u00a0E. (2017).\u00a0<a href=\"https:\/\/cbb.uw.edu.pl\/wp-content\/uploads\/2016\/01\/Abstract_ASBH_EK.pdf\">Pharmaceutical industry ethics. Is there a need for bioethicists-whistleblowers?<\/a>,\u00a019th Annual Meeting of The American Society for Bioethics and Humanities,\u00a0The American Society for Bioethics and Humanities (ASBH). Kansas City. Stany Zjednoczone, 19-22 pa\u017adziernika.<\/li>\n<li><strong>Kaczmarek<\/strong>, E. (2017).\u00a0<a href=\"https:\/\/cbb.uw.edu.pl\/wp-content\/uploads\/2016\/01\/Abstract_ESPMH_EK.pdf\">Disease mongering \u2013 the case of advertising drugs for restless legs syndrome in Poland<\/a>, 31st European Conference on Philosophy of Medicine and Health Care. The European Society for Philosophy of Medicine and Health Care (ESMPH). Belgrad, Serbia, 16-19 sierpnia.<\/li>\n<li><strong>Kaczmarek<\/strong>, E. (2017).\u00a0<a href=\"https:\/\/cbb.uw.edu.pl\/wp-content\/uploads\/2016\/01\/Abstract_WAML_EK.pdf\">Legal regulations of pharmaceutical advertising in Poland \u2013 bioethical challenges<\/a>,\u00a023rd World Association for Medical Law (WAML) World Congress for Medical Law (WAML),\u00a0Baku, Azerbaijan, 10-13 lipca.<\/li>\n<li><strong>Kaczmarek<\/strong>, E. (2016).\u00a0<a href=\"https:\/\/cbb.uw.edu.pl\/wp-content\/uploads\/2016\/01\/Abstrakt_Zdrowie-publiczne_EK.pdf\">Wsparcie finansowe firm farmaceutycznych dla organizacji pacjent\u00f3w \u2013 ukryty lobbing czy demokratyzacja medycyny?<\/a>, \u201eBioetyka a zdrowie publiczne\u201d\u00a0\u2013 konferencja naukowa organizowana przez\u00a0Komitet Bioetyki przy Prezydium Polskiej Akademii Nauk, Centrum Bioetyki i Bioprawa Instytutu Filozofii Uniwersytetu Warszawskiego, Polski Oddzia\u0142 the UNESCO Chair in Bioethics (Haifa), 9 \u2013 10 grudnia 2016, Pa\u0142ac Staszica, Warszawa<\/li>\n<li><strong>Kaczmarek<\/strong>, E. (2016). <a href=\"http:\/\/cbb.uw.edu.pl\/wp-content\/uploads\/2016\/01\/Abstract_Leuven_EK.pdf\"><em>Health, risk and responsibility<\/em><\/a>, The 2016 EACME Annual Conference &#8211; 30 Years of European Bioethics. The European Association of Centres of Medical Ethics (EACME). Leuven, Belgium, 8-10 September.<\/li>\n<li><strong>Kaczmarek<\/strong>, E. (2016). <a href=\"http:\/\/cbb.uw.edu.pl\/wp-content\/uploads\/2016\/01\/Abstract_Zagreb_EK.pdf\"><em>Lobbying in the healthcare systems \u2013 a challenge for bioethics?<\/em><\/a>, 30th European Conference on Philosophy of Medicine and Health Care. The European Society for Philosophy of Medicine and Health Care (ESMPH). Zagreb, Croatia, 17-20 August.<\/li>\n<li><strong>Kaczmarek<\/strong>, E. (2016).\u00a0<em>Between public good and private interest &#8211; the management of secrecy as the policy of transparency<\/em>, Conference &#8211; &#8220;Secret politics: history, modern forms and significance&#8221;, Department of Political Philosophy, Institute of Philosophy, University of Warsaw, Poland, Warsaw, 24 June.<\/li>\n<li><strong>Kaczmarek<\/strong>, E. (2016). <a href=\"http:\/\/cbb.uw.edu.pl\/wp-content\/uploads\/2016\/01\/Abstract_IAB_EK.pdf\"><em>Is Bioethics only a Side Effect of Global Biopolitics? Biocapital and the Recent Critique of Bioethics<\/em><\/a>, 13th World Congress of Bioethics \u2013 Individuals, Public Interests and Public Goods: What is the Contribution of Bioethics?. The International Association of Bioethics (IAB). Edinburgh, Scotland, 14-17 June. [Poster]<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>PROJECT SETTLED\u00a0 Project title:\u00a0Activity of pharmaceutical industry &#8211; ethical challenges and new biopolitics Principal investigator: dr Emilia Kaczmarek Financing: National Science Centre,\u00a0Preludium\u00a09 Project Period: 2016-2018 Project no.\u00a02015\/17\/N\/HS1\/02122 Project goals:\u00a0The main objective of the project is to demonstrate the biopolitical nature of the activity of pharmaceutical industry and to evaluate this activity from the point of\u2026 <span class=\"read-more\"><a href=\"https:\/\/cbb.uw.edu.pl\/en\/grants\/pharmabusiness-ethics-and-biopolitics\/\">Read More &raquo;<\/a><\/span><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":829,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-881","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pharmaceutical business | CBB<\/title>\n<meta name=\"description\" content=\"Pharmaceutical business - ethical challenges and new biopolitics |\u00a0Principal investigator: Emilia Kaczmarek MA\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cbb.uw.edu.pl\/en\/grants\/pharmabusiness-ethics-and-biopolitics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharmaceutical business | CBB\" \/>\n<meta property=\"og:description\" content=\"Pharmaceutical business - ethical challenges and new biopolitics |\u00a0Principal investigator: Emilia Kaczmarek MA\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cbb.uw.edu.pl\/en\/grants\/pharmabusiness-ethics-and-biopolitics\/\" \/>\n<meta property=\"og:site_name\" content=\"Center for Bioethics and Biolaw\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-19T14:58:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cbb.uw.edu.pl\/wp-content\/uploads\/2024\/03\/logo-NCN-horozin-en.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cbb.uw.edu.pl\\\/en\\\/grants\\\/pharmabusiness-ethics-and-biopolitics\\\/\",\"url\":\"https:\\\/\\\/cbb.uw.edu.pl\\\/en\\\/grants\\\/pharmabusiness-ethics-and-biopolitics\\\/\",\"name\":\"Pharmaceutical business | CBB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cbb.uw.edu.pl\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/cbb.uw.edu.pl\\\/en\\\/grants\\\/pharmabusiness-ethics-and-biopolitics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/cbb.uw.edu.pl\\\/en\\\/grants\\\/pharmabusiness-ethics-and-biopolitics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cbb.uw.edu.pl\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/logo-NCN-horozin-en.png\",\"datePublished\":\"2016-01-28T13:42:59+00:00\",\"dateModified\":\"2024-03-19T14:58:02+00:00\",\"description\":\"Pharmaceutical business - ethical challenges and new biopolitics |\u00a0Principal investigator: Emilia Kaczmarek MA\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cbb.uw.edu.pl\\\/en\\\/grants\\\/pharmabusiness-ethics-and-biopolitics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cbb.uw.edu.pl\\\/en\\\/grants\\\/pharmabusiness-ethics-and-biopolitics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/cbb.uw.edu.pl\\\/en\\\/grants\\\/pharmabusiness-ethics-and-biopolitics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cbb.uw.edu.pl\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/logo-NCN-horozin-en.png\",\"contentUrl\":\"https:\\\/\\\/cbb.uw.edu.pl\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/logo-NCN-horozin-en.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cbb.uw.edu.pl\\\/en\\\/grants\\\/pharmabusiness-ethics-and-biopolitics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Strona g\u0142\u00f3wna\",\"item\":\"https:\\\/\\\/cbb.uw.edu.pl\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Projects\",\"item\":\"https:\\\/\\\/cbb.uw.edu.pl\\\/en\\\/grants\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Pharmabusiness, ethics and biopolitics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cbb.uw.edu.pl\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/cbb.uw.edu.pl\\\/en\\\/\",\"name\":\"Center for Bioethics and Biolaw\",\"description\":\"Institute of Philosophy, University of Warsaw\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cbb.uw.edu.pl\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pharmaceutical business | CBB","description":"Pharmaceutical business - ethical challenges and new biopolitics |\u00a0Principal investigator: Emilia Kaczmarek MA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cbb.uw.edu.pl\/en\/grants\/pharmabusiness-ethics-and-biopolitics\/","og_locale":"en_US","og_type":"article","og_title":"Pharmaceutical business | CBB","og_description":"Pharmaceutical business - ethical challenges and new biopolitics |\u00a0Principal investigator: Emilia Kaczmarek MA","og_url":"https:\/\/cbb.uw.edu.pl\/en\/grants\/pharmabusiness-ethics-and-biopolitics\/","og_site_name":"Center for Bioethics and Biolaw","article_modified_time":"2024-03-19T14:58:02+00:00","og_image":[{"url":"https:\/\/cbb.uw.edu.pl\/wp-content\/uploads\/2024\/03\/logo-NCN-horozin-en.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cbb.uw.edu.pl\/en\/grants\/pharmabusiness-ethics-and-biopolitics\/","url":"https:\/\/cbb.uw.edu.pl\/en\/grants\/pharmabusiness-ethics-and-biopolitics\/","name":"Pharmaceutical business | CBB","isPartOf":{"@id":"https:\/\/cbb.uw.edu.pl\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cbb.uw.edu.pl\/en\/grants\/pharmabusiness-ethics-and-biopolitics\/#primaryimage"},"image":{"@id":"https:\/\/cbb.uw.edu.pl\/en\/grants\/pharmabusiness-ethics-and-biopolitics\/#primaryimage"},"thumbnailUrl":"https:\/\/cbb.uw.edu.pl\/wp-content\/uploads\/2024\/03\/logo-NCN-horozin-en.png","datePublished":"2016-01-28T13:42:59+00:00","dateModified":"2024-03-19T14:58:02+00:00","description":"Pharmaceutical business - ethical challenges and new biopolitics |\u00a0Principal investigator: Emilia Kaczmarek MA","breadcrumb":{"@id":"https:\/\/cbb.uw.edu.pl\/en\/grants\/pharmabusiness-ethics-and-biopolitics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cbb.uw.edu.pl\/en\/grants\/pharmabusiness-ethics-and-biopolitics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cbb.uw.edu.pl\/en\/grants\/pharmabusiness-ethics-and-biopolitics\/#primaryimage","url":"https:\/\/cbb.uw.edu.pl\/wp-content\/uploads\/2024\/03\/logo-NCN-horozin-en.png","contentUrl":"https:\/\/cbb.uw.edu.pl\/wp-content\/uploads\/2024\/03\/logo-NCN-horozin-en.png"},{"@type":"BreadcrumbList","@id":"https:\/\/cbb.uw.edu.pl\/en\/grants\/pharmabusiness-ethics-and-biopolitics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Strona g\u0142\u00f3wna","item":"https:\/\/cbb.uw.edu.pl\/en\/"},{"@type":"ListItem","position":2,"name":"Projects","item":"https:\/\/cbb.uw.edu.pl\/en\/grants\/"},{"@type":"ListItem","position":3,"name":"Pharmabusiness, ethics and biopolitics"}]},{"@type":"WebSite","@id":"https:\/\/cbb.uw.edu.pl\/en\/#website","url":"https:\/\/cbb.uw.edu.pl\/en\/","name":"Center for Bioethics and Biolaw","description":"Institute of Philosophy, University of Warsaw","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cbb.uw.edu.pl\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/cbb.uw.edu.pl\/en\/wp-json\/wp\/v2\/pages\/881","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cbb.uw.edu.pl\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cbb.uw.edu.pl\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cbb.uw.edu.pl\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cbb.uw.edu.pl\/en\/wp-json\/wp\/v2\/comments?post=881"}],"version-history":[{"count":17,"href":"https:\/\/cbb.uw.edu.pl\/en\/wp-json\/wp\/v2\/pages\/881\/revisions"}],"predecessor-version":[{"id":10648,"href":"https:\/\/cbb.uw.edu.pl\/en\/wp-json\/wp\/v2\/pages\/881\/revisions\/10648"}],"up":[{"embeddable":true,"href":"https:\/\/cbb.uw.edu.pl\/en\/wp-json\/wp\/v2\/pages\/829"}],"wp:attachment":[{"href":"https:\/\/cbb.uw.edu.pl\/en\/wp-json\/wp\/v2\/media?parent=881"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}